Assessing quality of life in lymphoma patients one year after chemotherapy
Quality of Life in Lymphoma Patients and Cancer Care Pathway One Year Post-chemotherapy
This study looks at how lymphoma patients feel one year after finishing their first round of chemotherapy to see if they have any physical or emotional challenges that affect their quality of life.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Toulouse Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Toulouse) |
| Trial ID | NCT04187118 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on lymphoma patients who have completed their first line of chemotherapy and are in complete response. It aims to evaluate the evolution of physical and psychological complications that may affect their quality of life one year post-treatment. Patients will complete self-administered questionnaires online to assess various factors such as anxiety, depression, and social isolation. The study also seeks to identify effective cancer care pathways that can help mitigate the risk of reduced quality of life in these patients.
Who should consider this trial
Good fit: Ideal candidates are lymphoma patients who have achieved complete response after their first line of chemotherapy.
Not a fit: Patients who are under legal guardianship or unable to provide consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved support and care strategies for lymphoma patients after chemotherapy, enhancing their overall quality of life.
How similar studies have performed: While there have been studies focusing on quality of life in cancer patients, this specific approach to evaluating post-chemotherapy outcomes in lymphoma patients is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients being in complete response after a first therapy for lymphoma * Malignant lymphoma (Hodgkin or non-Hodgkin) treated by anthracyclines with a minimum of 6 cycles, followed or not by autologous hematopoietic stem cell transplantation * Patients informed of the study and not opposed to the research Exclusion Criteria: * Patients under legal guardian . * Patients unavailable to formulate non-opposition to the study
Where this trial is running
Toulouse
- University Hospital Toulouse — Toulouse, France (Recruiting)
Study contacts
- Principal investigator: Loïc YSEBAERT, MD, PhD — University Hospital, Toulouse
- Study coordinator: Loïc YSEBAERT, MD, PhD
- Email: ysebaert.loic@iuct-oncopole.fr
- Phone: 561145940
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.